Intracellular delivery of cell-penetrating peptide-transcriptional factor fusion protein and its role in selective osteogenesis

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 1153-1166

  Suh, Jin Sook ^a   Lee, Jue Yeon ^b   Choi, Yoon Jung ^a   You, Hyung Keun ^c   Hong, Seong Doo ^a   Chung, Chong Pyoung ^b   Park, Yoon Jeong ^a,b  

^a Seoul National University   (South Korea)

^b Nano Intelligent Biomedical Engineering Corporation (NIBEC)   (South Korea)

^c Wonkwang University   (South Korea)

Author keywords

Bone tissue engineering; Low molecular weight protamine (LMWP); Protein transduction; Selective osteogenesis; Transcriptional coactivator with PDZ binding motif (TAZ)

Indexed keywords

ALGINIC ACID; BIOLOGICAL MARKER; BIOMATERIAL; CELL PENETRATING PEPTIDE; FATTY ACID BINDING PROTEIN 2; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHARMACEUTICS,PHC; PROTEIN LMWP; PROTEIN TAZ; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; BONE PROSTHESIS; GLUCURONIC ACID; HEXURONIC ACID; HYBRID PROTEIN; PROTAMINE; TAZ PROTEIN, HUMAN;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED RELEASE FORMULATION; CYTOSOL; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; GEL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MALE; MESENCHYMAL STEM CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; PROTEIN EXPRESSION; RABBIT; SKULL DEFECT; TISSUE ENGINEERING; TISSUE REGENERATION; ADMINISTRATION AND DOSAGE; ANIMAL; BONE PROSTHESIS; CYTOLOGY; DRUG EFFECTS; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; NANOMEDICINE; PHYSIOLOGY; PROCEDURES;

ADIPOGENESIS; ALGINATES; ANIMALS; BONE SUBSTITUTES; CELL DIFFERENTIATION; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; NANOMEDICINE; OSTEOGENESIS; PROTAMINES; RABBITS; RECOMBINANT FUSION PROTEINS; TISSUE ENGINEERING; TRANSCRIPTION FACTORS;

EID: 84897821712     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S55433     Document Type: Article

References (44)

1. Crombez L, Morris MC, Deshayes S, Heitz F, Divita G. Peptide-based nanoparticle for ex vivo and in vivo drug delivery. Curr Pharm Des. 2008;14:3656-3665.
2. Jones SW, Christison R, Bundell K, et al. Characterisation of cellpenetrating peptide-mediated peptide delivery. Br J Pharmacol. 2005;145:1093-1102.
3. Zhang K, Fang H, Chen Z, Taylor JS, Wooley KL. Shape effects of nanoparticles conjugated with cell-penetrating peptides (HIV Tat PTD) on CHO cell uptake. Bioconjug Chem. 2008;19:1880-1887.
4. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem. 2003;278:31192-31201.
5. Rothman JE. Mechanisms of intracellular protein transport. Nature. 1994;372:55-63.
6. Giorello L, Clerico L, Pescarolo MP, et al. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res. 1998;58: 3654-3659.
7. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A. 1994;91:664-668.
8. Jo D, Nashabi A, Doxsee C, et al. Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase. Nat Biotechnol. 2001;19:929-933.
9. Suh JS, Lee JY, Choi YS, et al. Efficient labeling of mesenchymal stem cells using cell permeable magnetic nanoparticles. Biochem Biophys Res Commun. 2009;379:669-675.
10. Fan H, Liu H, Wong EJ, Toh SL, Goh JC. In vivo study of anterior cruciate ligament regeneration using mesenchymal stem cells and silk scaffold. Biomaterials. 2008;29:3324-3337.
11. Tai K, Pelled G, Sheyn D, et al. Nanobiomechanics of repair bone regenerated by genetically modified mesenchymal stem cells. Tissue Eng Part A, 2008;14:1709-1720.
12. Zhou XZ, Leung VY, Dong QR, Cheung KM, Chan D, Lu WW. Mesenchymal stem cell-based repair of articular cartilage with polygly-colic acid-hydroxyapatite biphasic scaffold. Int J Artif Organs. 2008;31: 480-489.
13. Cowan CM, Aalami OO, Shi YY, et al. Bone morphogenetic protein 2 and retinoic acid accelerate in vivo bone formation, osteoclast recruitment, and bone turnover. Tissue Eng. 2005;11:645-658.
14. Pang EK, Im SU, Kim CS, et al. Effect of recombinant human bone morphogenetic protein-4 dose on bone formation in a rat calvarial defect model. J Periodontol. 2004;75:1364-1370.
15. Sekiya I, Larson BL, Vuoristo JT, Reger RL, Prockop DJ. Comparison of effect of BMP-2,-4, and 6 on in vitro cartilage formation of human adult stem cells from bone marrow stroma. Cell Tissue Res. 2005;320: 269-276.
16. Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene. 2006;25:685-692.
17. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res. 2004;2: 141-149.
18. Hong JH, Yaffe MB. TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle. 2006;5:176-179.
19. Cui CB, Cooper LF, Yang X, Karsenty G, Aukhil I. Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol. 2003;23:1004-1013.
20. Hong JH, Hwang ES, McManus MT, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science. 2005;309:1074-1078.
21. Byun MR, Jeong H, Bae SJ, et al. TAZ is required for the osteogenic and anti-adipogenic activities of kaempferol. Bone. 2012;50:364-372.
22. Kanai F, Marignani PA, Sarbassova D, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 2000;19:6778-6791.
23. Murakami M, Nakagawa M, Olson EN, Nakagawa O. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci U S A. 2005;102:18034-18039.
24. Ohba S, Ikeda T, Kugimiya F, et al. Identification of a potent combination of osteogenic genes for bone regeneration using embryonic stem (ES) cell-based sensor. FASEB J. 2007;21:1777-1787.
25. Park YJ, Chang LC, Liang JF, Moon C, Chung CP, Yang VC. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J. 2005;19:1555-1557.
26. Suh JS, Kim KS, Lee JY, Choi YJ, Chung CP, Park YJ. A cell-permeable fusion protein for the mineralization of human dental pulp stem cells. J Dent Res. 2012;91:90-96.
27. Lee LM, Chang LC, Wrobleski S, Wakefield TW, Yang VC. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci. 2001;3:E19.
28. Tsui B, Singh VK, Liang JF, Yang VC. Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue. Thromb Res. 2001;101:417-420.
29. Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol. 1996;12:575-625.
30. Tung CH, Mueller S, Weissleder R. Novel branching membrane translocational peptide as gene delivery vector. Bioorg Med Chem. 2002;10:3609-3614.
31. Choi YS, Lee JY, Suh JS, et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials. 2010;31:1429-1443.
32. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med. 2004;8:301-316.
33. Wang EA, Israel DI, Kelly S, Luxenberg DP. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors. 1993;9:57-71.
34. Asahina I, Sampath TK, Hauschka PV. Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Exp Cell Res. 1996;222:38-47.
35. Katagiri T, Yamaguchi A, Ikeda T, et al. The nonosteogenic mouse pluripotent cell line, C3h10t1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun. 1990;172:295-299.
36. Kato S, Kawabata N, Suzuki N, Ohmura M, Takagi M. Bone morphogenetic protein-2 induces the differentiation of a mesenchymal progenitor cell line, ROB-C26, into mature osteoblasts and adipocytes. Life Sci. 2009;84:302-310.
37. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int. 2001;69: 46-50.
38. Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res. 1971;80:147-154.
39. Choi YJ, Lee JY, Park JH, et al. The identification of a heparin binding domain peptide from bone morphogenetic protein-4 and its role on osteogenesis. Biomaterials. 2010;31:7226-7238.
40. Minear S, Leucht P, Jiang J, et al. Wnt proteins promote bone regeneration. Sci Transl Med. 2010;2:29-30.
41. Huang YC, Simmons C, Kaigler D, Rice KG, Mooney DJ. Bone regeneration in a rat cranial defect with delivery of PEI-condensed plasmid DNA encoding for bone morphogenetic protein-4 (BMP-4). Gene Ther. 2005;12:418-426.
42. Kim YS, Kim SH, Kim KH, et al. Rabbit maxillary sinus augmentation model with simultaneous implant placement: differential responses to the graft materials. J Periodontal Implant Sci. 2012;42:204-211.
43. Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery. 2008;62:ONS423-ONS431; discussion ONS431.
44. Vaidya R, Sethi A, Bartol S, Jacobson M, Coe C, Craig JG. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions. J Spinal Disord Tech. 2008;21:557-562.